Form 4: Enanta Pharma Director Granted 20,000 Stock Options

Enanta Pharmaceuticals director Terry Vance was granted 20,000 stock options with an exercise price of $14.17, vesting over one year.

Summary

• Terry Vance, a Director of Enanta Pharmaceuticals Inc. (ENTA), was granted 20,000 stock options.
• The options have an exercise price of $14.17 per share.
• The transaction date for this grant was March 11, 2026.
• The options will become exercisable monthly in substantially equal installments over one year, beginning from the grant date of March 11, 2026.
• The final monthly installment will vest no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.
• The options have an expiration date of March 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard compensation disclosure for a director, which is neither significantly positive nor negative for the company's immediate outlook.

Positives

• The grant of stock options aligns the director's long-term interests with those of the shareholders, incentivizing performance.
• The options have a 10-year expiration period, providing a significant window for potential value realization.

Negatives

• The grant introduces a minor potential for future share dilution if the options are exercised.

Future Outlook

The stock options will vest monthly over one year, starting March 11, 2026, with the final vesting installment occurring before the 2027 annual meeting of stockholders. This provides a future incentive structure for the director.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align leadership interests with long-term shareholder value creation.

Stakeholder Impact

• Shareholders: Minor potential for future dilution upon exercise of options, but also potential for increased director alignment with long-term company performance.
• Director (Terry Vance): Receives a significant equity incentive, aligning personal financial interests with the company's stock performance.

Next Steps

• The stock options will begin vesting monthly from March 11, 2026, over a one-year period.
• The director may choose to exercise the vested options at any point before the expiration date of March 11, 2036, assuming the stock price is above the exercise price.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Vesting Schedule